Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

An integrated epidemiological and neural net model of the warfarin effect in managed care patients.

Jacobs DM, Stefanovic F, Wilton G, Gomez-Caminero A, Schentag JJ.

Clin Pharmacol. 2017 May 18;9:55-64. doi: 10.2147/CPAA.S136243. eCollection 2017.

2.

Population pharmacokinetics of levofloxacin in Korean patients.

Kiem S, Ryu SM, Lee YM, Schentag JJ, Kim YW, Kim HK, Jang HJ, Joo YD, Jin K, Shin JG, Ghim JL.

J Chemother. 2016 Aug;28(4):308-13. doi: 10.1179/1973947815Y.0000000033.

PMID:
25976699
3.

Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus.

Kiem S, Schentag JJ.

Infect Chemother. 2014 Dec;46(4):219-25. doi: 10.3947/ic.2014.46.4.219. Epub 2014 Dec 29. Review.

4.

Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.

Paladino JA, Jacobs DM, Shields RK, Taylor J, Bader J, Adelman MH, Wilton GJ, Crane JK, Schentag JJ.

Int J Antimicrob Agents. 2014 Dec;44(6):557-63. doi: 10.1016/j.ijantimicag.2014.07.024. Epub 2014 Sep 16.

PMID:
25282169
5.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases.

Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24. Review.

6.

Correlations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia.

Kiem S, Schentag JJ.

Infect Chemother. 2013 Sep;45(3):283-91. doi: 10.3947/ic.2013.45.3.283. Epub 2013 Sep 27.

7.

Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus.

Monte SV, Caruana JA, Ghanim H, Sia CL, Korzeniewski K, Schentag JJ, Dandona P.

Surgery. 2012 Apr;151(4):587-93. doi: 10.1016/j.surg.2011.09.038. Epub 2011 Nov 16.

PMID:
22088821
8.
9.

Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.

Monte SV, Schentag JJ, Adelman MH, Paladino JA.

J Diabetes Sci Technol. 2010 Mar 1;4(2):382-90.

10.

Glucose supply and insulin demand dynamics of antidiabetic agents.

Monte SV, Schentag JJ, Adelman MH, Paladino JA.

J Diabetes Sci Technol. 2010 Mar 1;4(2):365-81.

12.

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

File TM Jr, Monte SV, Schentag JJ, Paladino JA, Klugman KP, Lavin B, Yu VL, Singer ME, Adelman MH.

Int J Antimicrob Agents. 2009 Jan;33(1):58-64. doi: 10.1016/j.ijantimicag.2008.07.019. Epub 2008 Oct 1.

PMID:
18835762
13.

Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance.

Paladino JA, Sunderlin JL, Singer ME, Adelman MH, Schentag JJ.

Am J Health Syst Pharm. 2008 Jun 15;65(12):1154-9. doi: 10.2146/ajhp070435.

PMID:
18541686
14.

Costs of treating lower respiratory tract infections.

Monte SV, Paolini NM, Slazak EM, Schentag JJ, Paladino JA.

Am J Manag Care. 2008 Apr;14(4):190-6.

15.

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

McKinnon PS, Paladino JA, Schentag JJ.

Int J Antimicrob Agents. 2008 Apr;31(4):345-51. doi: 10.1016/j.ijantimicag.2007.12.009. Epub 2008 Mar 4.

PMID:
18313273
16.

The economics of Clostridium difficile-associated disease for providers and payers.

Paladino JA, Schentag JJ.

Clin Infect Dis. 2008 Feb 15;46(4):505-6. doi: 10.1086/526531. No abstract available.

PMID:
18197762
17.

Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals .

Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, Smulders M, Gemmen E, Bharmal M.

Infect Control Hosp Epidemiol. 2008 Jan;29(1):16-24. doi: 10.1086/524327. Erratum in: Infect Control Hosp Epidemiol. 2009 Aug;30(8):815.

PMID:
18171182
18.

A case series of macrolide treatment failures in community acquired pneumonia.

Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ.

J Chemother. 2007 Oct;19(5):536-45.

PMID:
18073153
19.

National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003).

Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, Smulders M, Gemmen E, Bharmal M.

Clin Infect Dis. 2007 Nov 1;45(9):1132-40. Epub 2007 Sep 21.

PMID:
17918074
20.

Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Kiem S, Schentag JJ.

Antimicrob Agents Chemother. 2008 Jan;52(1):24-36. Epub 2007 Sep 10. Review. No abstract available.

21.

Observations on vancomycin use in U.S. hospitals.

Paladino JA, Sunderlin JL, Adelman MH, Singer ME, Schentag JJ.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1633-41.

PMID:
17646567
22.
23.

Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.

Schentag JJ, Klugman KP, Yu VL, Adelman MH, Wilton GJ, Chiou CC, Patel M, Lavin B, Paladino JA.

Int J Antimicrob Agents. 2007 Sep;30(3):264-9. Epub 2007 Jun 22.

PMID:
17587549
24.

Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.

Paladino JA, Eubanks DA, Adelman MH, Schentag JJ.

J Am Geriatr Soc. 2007 May;55(5):651-7.

PMID:
17493183
25.

Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.

Schentag JJ, Hill G, Chu T, Rayner CR.

J Clin Pharmacol. 2007 Jun;47(6):689-96. Epub 2007 Apr 24.

PMID:
17456583
26.

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Moise PA, Sakoulas G, Forrest A, Schentag JJ.

Antimicrob Agents Chemother. 2007 Jul;51(7):2582-6. Epub 2007 Apr 23.

27.

Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.

Moise PA, Schentag JJ.

Curr Opin Infect Dis. 1998 Dec;11(6):673-80.

PMID:
17035742
28.

Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors.

LeBlanc JM, Dasta JF, Pruchnicki MC, Schentag JJ.

J Clin Pharmacol. 2006 Sep;46(9):968-80. Review.

PMID:
16920891
29.
30.

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database.

Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmen E.

Arch Intern Med. 2005 Aug 8-22;165(15):1756-61.

PMID:
16087824
31.

New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.

Zhou XF, Zhang L, Tseng E, Scott-Ramsay E, Schentag JJ, Coburn RA, Morris ME.

Drug Metab Dispos. 2005 Mar;33(3):321-8. Epub 2004 Dec 7.

PMID:
15585608
32.

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.

Clin Pharmacokinet. 2004;43(13):925-42.

PMID:
15509186
33.

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr.

Clin Infect Dis. 2004 Jun 15;38(12):1700-5. Epub 2004 May 21.

PMID:
15227615
34.

Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):2061-8.

35.

Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis.

Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ.

Ann Plast Surg. 2004 Apr;52(4):385-90.

PMID:
15084884
36.

Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ.

Infection. 2004 Feb;32(1):8-14.

PMID:
15007736
37.

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ.

Clin Pharmacokinet. 2003;42(15):1411-23.

PMID:
14674791
38.

Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.

Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, Schentag JJ.

Am J Health Syst Pharm. 2003 Oct 1;60(19):1962-70.

PMID:
14531241
39.

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.

Schentag JJ, Meagher AK, Forrest A.

Ann Pharmacother. 2003 Oct;37(10):1478-88. Review.

PMID:
14519053
40.

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.

Schentag JJ, Meagher AK, Forrest A.

Ann Pharmacother. 2003 Sep;37(9):1287-98. Review.

PMID:
12921513
41.

Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.

Paladino JA, Sunderlin JL, Forrest A, Schentag JJ.

J Antimicrob Chemother. 2003 Sep;52(3):457-63. Epub 2003 Jul 29.

PMID:
12888598
42.

Pharmacokinetics and metabolism of moxifloxacin.

Moise PA, Birmingham MC, Schentag JJ.

Drugs Today (Barc). 2000 Apr;36(4):229-44.

PMID:
12879119
43.

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ.

Ann Oncol. 2003 May;14(5):795-801.

PMID:
12702536
44.

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ.

Antimicrob Agents Chemother. 2003 Feb;47(2):548-53.

45.

Economic consequences of antimicrobial resistance.

Paladino JA, Sunderlin JL, Price CS, Schentag JJ.

Surg Infect (Larchmt). 2002 Fall;3(3):259-67. Review.

PMID:
12542927
46.

Clinical experience with linezolid for the treatment of nocardia infection.

Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, Schentag JJ, Gimbel JF, Apodaca A, Schwartz MA, Rakita RM, Wallace RJ Jr.

Clin Infect Dis. 2003 Feb 1;36(3):313-8. Epub 2003 Jan 13.

PMID:
12539073
47.

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ.

Clin Infect Dis. 2003 Jan 15;36(2):159-68. Epub 2003 Jan 3.

PMID:
12522747
48.
49.

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.

Wilson R, Schentag JJ, Ball P, Mandell L; 068 Study Group.

Clin Ther. 2002 Apr;24(4):639-52.

PMID:
12017408
50.

Supplemental Content

Loading ...
Support Center